Journal of the American Medical Association  |  July 28, 2023

Read the Publication

Glucagon-like peptide 1 (GLP-1) receptor agonists were first approved for the treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive.

Read more here.

Latest publications See All